219 related articles for article (PubMed ID: 28783374)
21. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
[TBL] [Abstract][Full Text] [Related]
22. Utility of the Montreal Cognitive Assessment (MoCA) and its subset in HIV-associated neurocognitive disorder (HAND) screening.
Kim WJ; Ku NS; Lee YJ; Ahn JY; Kim SB; Ahn HW; Hong KW; Song JY; Cheong HJ; Kim WJ; Kim JM; Namkoong K; Choi JY; Kim E
J Psychosom Res; 2016 Jan; 80():53-7. PubMed ID: 26721548
[TBL] [Abstract][Full Text] [Related]
23. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Quick Mild Cognitive Impairment (Qmci) screen to the Montreal Cognitive Assessment (MoCA) in an Australian geriatrics clinic.
Clarnette R; O'Caoimh R; Antony DN; Svendrovski A; Molloy DW
Int J Geriatr Psychiatry; 2017 Jun; 32(6):643-649. PubMed ID: 27427212
[TBL] [Abstract][Full Text] [Related]
25. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I
AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542
[TBL] [Abstract][Full Text] [Related]
26. Properties of a brief assessment tool for longitudinal measurement of cognition in people living with HIV.
Brouillette MJ; Fellows LK; Finch L; Thomas R; Mayo NE
PLoS One; 2019; 14(3):e0213908. PubMed ID: 30908501
[TBL] [Abstract][Full Text] [Related]
27. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada.
Robertson K; Bayon C; Molina JM; McNamara P; Resch C; Muñoz-Moreno JA; Kulasegaram R; Schewe K; Burgos-Ramirez A; De Alvaro C; Cabrero E; Guion M; Norton M; van Wyk J
AIDS Care; 2014; 26(12):1555-61. PubMed ID: 25029599
[TBL] [Abstract][Full Text] [Related]
28. An Abbreviated Montreal Cognitive Assessment (MoCA) for Dementia Screening.
Horton DK; Hynan LS; Lacritz LH; Rossetti HC; Weiner MF; Cullum CM
Clin Neuropsychol; 2015; 29(4):413-25. PubMed ID: 25978540
[TBL] [Abstract][Full Text] [Related]
29. Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia.
Mukherjee T; Sakthivel R; Fong HY; McStea M; Chong ML; Omar SF; Chin AV; Kamaruzzaman S; Kamarulzaman A; Rajasuriar R; Cysique LA
AIDS Behav; 2018 Oct; 22(10):3226-3233. PubMed ID: 29508103
[TBL] [Abstract][Full Text] [Related]
30. Subjective memory complaints, depressive symptoms and instrumental activities of daily living in mild cognitive impairment.
Ryu SY; Lee SB; Kim TW; Lee TJ
Int Psychogeriatr; 2016 Mar; 28(3):487-94. PubMed ID: 26555226
[TBL] [Abstract][Full Text] [Related]
31. Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment.
Anderson AM; Lennox JL; Nguyen ML; Waldrop-Valverde D; Tyor WR; Loring DW
J Neurovirol; 2016 Dec; 22(6):816-822. PubMed ID: 27245594
[TBL] [Abstract][Full Text] [Related]
32. Screening and facilitating further assessment for cognitive impairment after stroke: application of a shortened Montreal Cognitive Assessment (miniMoCA).
Campbell N; Rice D; Friedman L; Speechley M; Teasell RW
Disabil Rehabil; 2016; 38(6):601-4. PubMed ID: 26119578
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature.
Zipursky AR; Gogolishvili D; Rueda S; Brunetta J; Carvalhal A; McCombe JA; Gill MJ; Rachlis A; Rosenes R; Arbess G; Marcotte T; Rourke SB
AIDS; 2013 Sep; 27(15):2385-401. PubMed ID: 23751261
[TBL] [Abstract][Full Text] [Related]
34. Frequency and Correlates of Subjective Cognitive Impairment in HIV Disease.
Sheppard DP; Woods SP; Massman PJ; Gilbert PE
AIDS Behav; 2019 Mar; 23(3):617-626. PubMed ID: 30311103
[TBL] [Abstract][Full Text] [Related]
35. Interaction Effects between HIV and Aging on Selective Neurocognitive Impairment.
Ding Y; Lin H; Shen W; Wu Q; Gao M; He N
J Neuroimmune Pharmacol; 2017 Dec; 12(4):661-669. PubMed ID: 28470583
[TBL] [Abstract][Full Text] [Related]
36. Neurological soft signs as a marker of cognitive impairment severity in people living with HIV.
Toro P; Ceballos ME; Pesenti J; Inostroza M; Valenzuela D; Henríquez F; Forno G; Herold C; Schröder J; Calderón J
Psychiatry Res; 2018 Aug; 266():138-142. PubMed ID: 29870954
[TBL] [Abstract][Full Text] [Related]
37. The HIV Dementia Scale: predictive power in mild dementia and HAART.
Bottiggi KA; Chang JJ; Schmitt FA; Avison MJ; Mootoor Y; Nath A; Berger JR
J Neurol Sci; 2007 Sep; 260(1-2):11-5. PubMed ID: 17482212
[TBL] [Abstract][Full Text] [Related]
38. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons.
Overton ET; Azad TD; Parker N; Demarco Shaw D; Frain J; Spitz T; Westerhaus E; Paul R; Clifford DB; Ances BM
J Neurovirol; 2013 Feb; 19(1):109-16. PubMed ID: 23345074
[TBL] [Abstract][Full Text] [Related]
39. Neurological soft signs (NSS) and cognitive deficits in HIV associated neurocognitive disorder.
Forno G; Henríquez F; Ceballos ME; Gonzalez M; Schröder J; Toro P
Neuropsychologia; 2020 Sep; 146():107545. PubMed ID: 32593722
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
